Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

RVMDRevolution Medicines, Inc.Signing up patients

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Colorectal Cancer · CRC · Pancreatic Ductal Adenocarcinoma · PDAC · Gastrointestinal Cancer · Metastatic Pancreatic Ductal Adenocarcinoma

0Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

No warning signs right now. That's why the score is 0.

Score over time

Stage
Phase 1/2
Patients
1,130 (planned)
Started
May 24, 2024
Main results expected
Sep 30, 2028
Fully finished
Mar 30, 2030
Results posted
not yet

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • Adverse events (Subprotocols A-F)

    Measured over: Up to 3 years

  • Dose limiting toxicities (Subprotocols A-F)

    Measured over: 28 days

  • Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) as assessed by Blinded Independent Central Review (BICR)(Subprotocol G)

    Measured over: Up to 3 years

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • none

Raw record changes

  • none yet

Trial ID NCT06445062 · record last updated 2026-09-22 · checked 2026-11-09 15:47 UTC

See the official record on ClinicalTrials.gov (NCT06445062) ↗